Premature Ovarian Failure
Article Sidebar
Main Article Content
Abstract
Objective: To provide a rigorous, multidisciplinary synthesis of the epidemiological, genetic, immunological, and environmental factors contributing to Premature Ovarian Failure (POF), with particular attention to regional disparities, occupational exposures, the impact of chemotherapy, the occurrence and recurrence of endometrosis, and emerging fertility preservation strategies.
Design: A structured literature review with an emphasis on recent advances in genetic and immunological understanding.
Setting: Academic research and clinical insights from multidisciplinary contributors.
Patients: Individuals diagnosed with POF as reported in the literature.
Interventions: Review of literature concerning epidemiology, genetic mutations, immunological disorders, and surgical outcomes linked to POF.
Main outcome measures: Identification of both established and emerging risk factors, validation of genetic and immunological markers, and clarification of diagnostic and preventive clinical approaches.
Results: The prevalence of POF varies globally, affecting 1% of women under 40. Genetic factors, particularly mutations in the FMR1 and BMP15 genes, play a significant role, alongside autoimmune diseases. Chemotherapy is a leading iatrogenic cause, while endometriosis and ovarian cyst surgeries significantly contribute to diminished ovarian reserve.
Conclusion: POF is a multifactorial condition with rising incidence in specific subgroups. Improved early detection, standardized biomarker use, and expanded access to fertility preservation are essential. Targeted genomic and occupational risk screening may enable personalized interventions. Further genomic studies are needed to elucidate rare mutations and their impact.
Article Details
Copyright (c) 2025 Bulletti FM, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–614. Available from: https://doi.org/10.1056/nejmcp0808697 nejm.org+9nejm.org+9europepmc.org+9
Chapman C, Cree L, Shelling AN. The genetics of premature ovarian failure: current perspectives. Int J Womens Health. 2015;7:799–810. Available from: https://doi.org/10.2147/ijwh.s64024
Coulam CB, Adamson SC. Premature ovarian failure: evidence for a genetic basis. Hum Reprod Update. 1996;2(6):482–490.
Progetto Menopausa Italia Study Group. Premature ovarian failure: frequency and risk factors among women attending a network of menopause clinics in Italy. BJOG. 2003;110(1):59–63. Available from: https://doi.org/10.1016/S1470-0328(02)02929-4
Zhu X, Liu M, Dong R, Gao L, Hu J, Zhang X, et al. Mechanism exploration of environmental pollutants on premature ovarian insufficiency: a systematic review and meta-analysis. Reprod Sci. 2024;31:99–106. Available from: https://doi.org/10.1007/s43032-023-01326-5
Infertility. WHO. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/infertility
Zaake D, Amongin D, Beňová L, Kiwanuka SN, Nalwadda CK, et al. Prevalence, regional distribution, and determinants of infertility in Uganda between 2006 and 2016: analysis of three Demographic and Health Surveys. J Glob Health Rep. 2024;8:e2024008. Available from: https://doi.org/10.29392/001c.94212
Rossetti R, Di Pasquale E, Marozzi A, Bione S, Toniolo D, Grammatico P, et al. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat. 2009;30(5):804–810. Available from: https://doi.org/10.1002/humu.20961
Nash Z, Davies M. Premature ovarian insufficiency. BMJ. 2024;384. Available from: https://doi.org/10.1136/bmj-2023-077469
Bakalov VK, Anasti JN, Calis KA, Vanderhoof VH, Premkumar A, Chen S, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril. 2005;84(4):958–965. Available from: https://doi.org/10.1016/j.fertnstert.2005.04.060
Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000;169(1–2):123–131. Available from: https://doi.org/10.1016/S0303-7207(00)00365-8 journals.sagepub.com+8rep.bioscientifica.com+8journals.scholarsportal.info+8
Somigliana E, Vercellini P, Pasinato L. Endometriosis and ovarian reserve: a dangerous association. Endocrine. 2003;23(2–3):187–192.
Practice Committee of the American Society for Reproductive Medicine. Evidence‑based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline. Fertil Steril. 2021;116(1):36–47. Available from: https://doi.org/10.1016/j.fertnstert.2021.02.024
Ter Welle-Butalid ME, Derhaag JG, van Bree BE, Vriens IJH, Goddijn M, Balkenende EME, et al. Outcomes of female fertility preservation with cryopreservation of oocytes or embryos in the Netherlands: a population‑based study. Hum Reprod. 2024;39(12):2693–2701. Available from: https://doi.org/10.1093/humrep/deae243
Kasaven LS, Jones BP, Heath CR, Odia R, Green J, Petrie A, et al. Reproductive outcomes from ten years of elective oocyte cryopreservation. Arch Gynecol Obstet. 2022;306:1753–1760. Available from: https://doi.org/10.1007/s00404-022-06711-0
Walker Z, Lanes A, Ginsburg E. Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation. Reprod Biol Endocrinol. 2022;20:10. Available from: https://doi.org/10.1186/s12958-021-00884-0
Milachich T, Shterev A. Are there optimal numbers of oocytes, spermatozoa, and embryos in assisted reproduction? JBRA Assist Reprod. 2016;20(3):142–149. Available from: https://doi.org/10.5935/1518-0557.20160032
Sermondade N, Pasquier M, Ahdad‑Yata N, Fraison E, Grynberg M. Searching for the optimal number of oocytes to reach a live birth after in vitro fertilization: a systematic review with meta-analysis. F&S Rev. 2023;4(2):101–115. Available from: https://doi.org/10.1016/j.xfnr.2023.03.002
Goldman RH, Racowsky C, Farland LV, Munné S, Ribustello L, Fox JH. Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients. Hum Reprod. 2017;32(4):853–859. Available from: https://doi.org/10.1093/humrep/dex008
Cascante SD, Berkeley AS, Licciardi F, McCaffrey C, Grifo JA. Planned oocyte cryopreservation: the state of the ART. Reprod Biomed Online. 2023;47(6):103367. Available from: https://doi.org/10.1016/j.rbmo.2023.103367
Orvieto R. What is the expected live birth rate per thawed oocyte? Hum Reprod Update. 2024;30(5):648–649. Available from: https://doi.org/10.1093/humupd/dmae015